Lattanzi Roberta, Casella Ida, Fullone Maria Rosaria, Maftei Daniela, Vincenzi Martina, Miele Rossella
Department of Physiology and Pharmacology "Vittorio Erspamer", Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.
National Centre for Drug Research and Evaluation, Istituto Superiore di Sanità, 00161 Rome, Italy.
Curr Issues Mol Biol. 2024 Feb 17;46(2):1607-1620. doi: 10.3390/cimb46020104.
Melanocortin receptor accessory protein 2 (MRAP2) is a membrane protein that binds multiple G protein-coupled receptors (GPCRs) involved in the control of energy homeostasis, including prokineticin receptors. These GPCRs are expressed both centrally and peripherally, and their endogenous ligands are prokineticin 1 (PK1) and prokineticin 2 (PK2). PKRs couple all G-protein subtypes, such as Gαq/11, Gαs, and Gαi, and recruit β-arrestins upon PK2 stimulation, although the interaction between PKR2 and β-arrestins does not trigger receptor internalisation. MRAP2 inhibits the anorexigenic effect of PK2 by binding PKR1 and PKR2. The aim of this work was to elucidate the role of MRAP2 in modulating PKR2-induced β-arrestin-2 recruitment and β-arrestin-mediated signalling. This study could allow the identification of new specific targets for potential new drugs useful for the treatment of the various pathologies correlated with prokineticin, in particular, obesity.
黑皮质素受体辅助蛋白2(MRAP2)是一种膜蛋白,它能结合多种参与能量稳态控制的G蛋白偶联受体(GPCR),包括促动力蛋白受体。这些GPCR在中枢和外周均有表达,其内源配体是促动力蛋白1(PK1)和促动力蛋白2(PK2)。促动力蛋白受体与所有G蛋白亚型偶联,如Gαq/11、Gαs和Gαi,并在PK2刺激时募集β-抑制蛋白,尽管PKR2与β-抑制蛋白之间的相互作用不会触发受体内化。MRAP2通过结合PKR1和PKR2来抑制PK2的厌食作用。这项工作的目的是阐明MRAP2在调节PKR2诱导的β-抑制蛋白2募集和β-抑制蛋白介导的信号传导中的作用。这项研究可能有助于识别潜在新药的新特异性靶点,这些新药可用于治疗与促动力蛋白相关的各种疾病,尤其是肥胖症。